pillbase.ru

Saxenda

Active substance: liraglutide

INJECTION, SOLUTION · LIRAGLUTIDE 6 mg/mL

United StatesActive

Marketing holder: Novo Nordisk Pharmaceutical Industries, LP

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
EU 5
  • Ablymico
    liraglutide
    EMEA/H/C/006620
    STADA Arzneimittel AG
  • Liraglutide STADA
    liraglutide
    EMEA/H/C/006615
    STADA Arzneimittel AG
  • Saxenda
    liraglutide
    EMEA/H/C/003780
    Novo Nordisk A/S
  • Victoza
    liraglutide
    EMEA/H/C/001026
    Novo Nordisk A/S
  • Xultophy
    insulin degludec, liraglutide
    EMEA/H/C/002647
    Novo Nordisk A/S
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-490f-733b-8f13-cff36ad82dd1,01a1208c-b4a6-7152-a279-97efbfdd972e,01a1208c-d9b9-783f-8736-6ab8a3753c69,01a1208d-2e11-7e9c-a959-70e29965ecbb,01a1208d-ad9c-79e1-bc37-ecf88a2eb4a7;count=19 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
0169-2800
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 0169-2800 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 0169-2800 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 0169-2800 · Verified 2026-10-09 · open in source